Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers

Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers

Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and signal transducer and activator of transcription 3 (STAT3), have bee...

Full description

Bibliographic Details
Main Authors: Sara Manore, Chuling Zhuang, Mariana K. Najjar, Grace L. Wong, Shivani Bindal, Kounosuke Watabe, Jiayuh Lin, Hui-Wen Lo
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Cells
Subjects:
tGLI1
STAT3
IL-6
GP130
ketoconazole
bazedoxifene
Online Access:https://www.mdpi.com/2073-4409/13/24/2087

Internet

https://www.mdpi.com/2073-4409/13/24/2087

Similar Items